UNSPSC 51431708: Diltiazem hydrochloride

This classification denotes a calcium channel blocker with the molecular formula C22H26N2O4S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OLH94387TE, chemically known as 1,5-benzothiazepin-4(5h)-one, 3-(acetyloxy)-5-(2-(dimethylamino)ethyl)-2,3-dihydro-2-(4-methoxyphenyl)-, monohydrochloride, (+)-cis- but more generally known as diltiazem hydrochloride, which bears US NIH Compound Identifier 62920.

UNSPSC 51431708 Diltiazem hydrochloride, a Commodity code, covers the supply of this cardiac medication in injectable formulations to state and local emergency medical service providers, public health agencies, and cooperative purchasing consortiums. State and local governments procure diltiazem through sealed-bid purchases for emergency medical supplies, multi-source pharmaceutical cooperative contracts, and exploratory demand-aggregation initiatives for direct-to-manufacturer pharmacy programs. The issuing bodies include city fire rescue departments, state health and human services agencies, and multistate cooperative purchasing alliances that aggregate demand across participating state and local facilities. Recent solicitations show diltiazem appearing as one line item within broader advanced life support medication procurements and as part of generic pharmaceutical supply contracts that span hundreds of products across multiple therapeutic categories.

The code shows activity across Florida, Minnesota, and Texas. The City of Tampa's Purchasing Department issued sealed-bid solicitation 26P00188 in April 2026 for Advanced Life Support Medications including 1,020 units of Diltiazem 25mg vials, with bid responses due April 8, 2026 and a contract value of $40,000 and a one-year term with two optional renewal periods; the solicitation included a 5 percent Small Local Business Enterprise bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with responses due March 26, 2026, with products required available by May 15, 2026 and contracts effective July 1, 2026; diltiazem would be sourced through AmerisourceBergen Drug Corporation, Cardinal Health, or Morris & Dickson Co. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 exploring direct-to-manufacturer prescription programs, a preliminary market-gathering phase that may inform future solicitations for pharmaceutical supply.